Name: Recombinant Human Urokinase / uPA Protein (His Tag)
Brand: Beta LifeScience
SKU: BLPSN-4745
Availability: InStock

Recombinant Human Urokinase / uPA Protein (His Tag)

Catalog No.: BLPSN-4745

Product Overview

Tag	His
Host Species	Human
Accession	NP_002649.1
Synonym	ATF, BDPLT5, QPD, u-PA, UPA, URK
Background	Plasminogen activator, urokinase, also known as PLAU and uPA, is a serine protease which converts plasminogen to plasmin, a broad-spectrum protease active on extracellular matrix (ECM) components. It is involved in complement activation, cell migration, wound healing, and generation of localized extracellular proteolysis during tissue remodelling, pro-hormone conversion, carcinogenesis and neoplasia. Like many components of the blood coagulation, fibrinolytic and complement cascades, uPA has a modular structure, including three conserved domains: a growth factor-like domain (GFD, residues 1-49), a kringle domain (residues 5-131), linked by an interdomain linker or "connecting peptide" (CP, residues 132-158) to the serine protease domain (residues 159-411). uPA and its receptor (uPAR) have been implicated in a broad spectrum of pathophysiological processes, including fibrinolysis, proteolysis, inflammation, atherogenesis and plaque destabilization, all of which are involved in the pathogenesis of MI (myocardial infarction). The role of uPA is not only linked to its action as an enzyme. In fact, the mere binding of uPA on the cell surface also brings about two events that broaden the spectrum of its biological functions: (1) a conformational change of the receptor, which, in turn, affects its interaction with other proteins; (2) a signal transduction which modulates the expression of apoptosis-related genes. Besides its applications as a thrombolytic agent and as a prognostic marker for tumors, uPA may provide the basis for other therapies, as the structure of the receptor-binding domain of uPA has become a model for the design of anti-cancer molecules. Because of the causal involvment of uPA in cancer invasion and metastasis, the blockade of uPA interactions and activity with specific inhibitors is of interest for novel strategies in cancer therapy.
Description	A DNA sequence encoding the human PLAU (NP_002649.1) (Met 1-Leu 431) with a C-terminal His tag was expressed.
Source	HEK293
Predicted N Terminal	Ser 21
AA Sequence	Met 1-Leu 431
Molecular Weight	The secreted recombinant human PLAU comprises 422 a.a. with a predicted molecular mass of 46 kDa. As a result of glycosylation, rhPLAU migrates as three bands corresponding to the long A chain, B chain and unprocessed full-length PLAU with the molecular mass of 18, 32 and 50 kDa respectively in SDS-PAGE under reducing conditions.
Purity	>97% as determined by SDS-PAGE
Endotoxin	< 1.0 EU per μg of the protein as determined by the LAL method
Bioactivity	Measured by its binding ability in a functional ELISA. Immobilized human uPA at 5 ug/ml (100 ul/well) can bind mouse PLAUR with a linear ranger of 1.6-40 ng/ml.
Formulation	Lyophilized from sterile PBS, pH 7.4.
Stability	The recombinant proteins are stable for up to 1 year from date of receipt at -70°C.
Usage	For Research Use Only
Storage	Store the protein under sterile conditions at -20°C to -80°C. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.